Novel Method of Monitoring Trace Cytokines and Activated STAT Molecules in the Paws of Arthritic Mice using Multiplex Bead Technology

BMC Immunology

Volumn 11, Issue , 2010, Pages

  Lu, Lily D ^a   Stump, Kristine L ^a   Seavey, Matthew M ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFFER; COLLAGEN ANTIBODY; DEXAMETHASONE; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; STAT1 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE; MICROSPHERE; STAT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE COURSE; DISEASE MODEL; EXTRACTION; FEMALE; FOREFOOT; LABORATORY TEST; MOUSE; MULTIPLEX BEAD RESULT; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SWELLING; SYNOVIAL FLUID; ANIMAL; ARTHRITIS; CHEMICAL ANALYSIS; CHEMICALLY INDUCED DISORDER; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; PARACRINE SIGNALING; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHEMISTRY TECHNIQUES, ANALYTICAL; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MICROSPHERES; PARACRINE COMMUNICATION; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION;

EID: 78649505987     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-55     Document Type: Article

References (48)

1. Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010, 233:301-12. 10.1111/j.0105-2896.2009.00857.x, 20193007.
2. Gabriel SE. Heart disease and rheumatoid arthritis: understanding the risks. Ann Rheum Dis 2010, 69(Suppl 1):i61-64. 10.1136/ard.2009.119404, 19995747.
3. David AHK, Brand D, Rosloniec Edward F. The Mouse Model of Collagen-Induced Arthritis. Methods in Molecular Medicine 2004, 102:295-312. Totowa, NJ: Humana Press Inc, Perl A.
4. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD. Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:992-9. 10.1136/ard.2006.060822, 1954703, 17223651.
5. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004, 36:372-8. 10.1016/S1357-2725(03)00259-0, 14687914.
6. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008, 28:477-87. 10.1016/j.immuni.2008.03.002, 2782488, 18400190.
7. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006, 65:149-56. 10.1136/ard.2005.037929, 1798020, 16096332.
8. Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006, 65:1558-64. 10.1136/ard.2005.050385, 1798468, 16760256.
9. aAL Verdenius HHW. A quantitative study of decalcification methods in histology. J Clin Pathol 1958, 11:229-236. 10.1136/jcp.11.3.229, 479755, 13539226.
10. Eggert FM, Germain JP. Rapid demineralization in acidic buffers. Histochemistry 1979, 59:215-24. 10.1007/BF00495669, 107151.
11. Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009, 15:781-7. 10.1038/nm.1978, 19525961.
12. Chia WT, LT Y, Chen YW, HS L, Chang DM, Sytwu HK. IL-1beta in irrigation fluid and mRNA expression in synovial tissue of the knee joint as therapeutic markers of inflammation in collagen antibody-induced arthritis. Dis Markers 2009, 26:1-7.
13. Chia WT, Chen YW, Cheng LY, Lee HS, Chang DM, Sytwu HK. MMP-9 mRNA as a therapeutic marker in acute and chronic stages of arthritis induced by type II collagen antibody. J Formos Med Assoc 2008, 107:245-52. 10.1016/S0929-6646(08)60143-6, 18400610.
14. West K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders. Curr Opin Investig Drugs 2009, 10:491-504.
15. Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, Zwillich SH. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2010, 69:413-6. 10.1136/ard.2009.108159, 19587388.
16. Billich A. Drug evaluation: apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 2007, 10:53-9.
17. McCluggage LK, Scholtz JM. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2010, 44:135-44. 10.1345/aph.1M227, 20118145.
18. Nandakumar KS, Holmdahl R. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J Immunol Methods 2005, 304:126-36. 10.1016/j.jim.2005.06.017, 16125192.
19. Geyer M, Muller-Ladner U. Actual status of antiinterleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol 2010, 22:246-51. 10.1097/BOR.0b013e3283373fa0, 20150813.
20. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009, 5:531-41. 10.1038/nrrheum.2009.182, 19798027.
21. Fitzgerald LKA, Gearing AJH, Callard RE. The Cytokine Facts Book. 2001, San Diego, California, USA: Academic Press, 2.
22. Gorak PM, Engwerda CR, Kaye PM. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol 1998, 28:687-95. 10.1002/(SICI)1521-4141(199802)28:02<687::AID-IMMU687>3.0.CO;2-N, 9521079.
23. D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992, 176:1387-98. 10.1084/jem.176.5.1387, 2119437, 1357073.
24. Hakonarson H, Maskeri N, Carter C, Grunstein MM. Regulation of TH1- and TH2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle. J Clin Invest 1999, 103:1077-87. 10.1172/JCI5809, 408262, 10194481.
25. DeForge LE, Remick DG. Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem Biophys Res Commun 1991, 174:18-24. 10.1016/0006-291X(91)90478-P, 1989598.
26. Cho YG, Cho ML, Min SY, Kim HY. Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis. Autoimmun Rev 2007, 7:65-70. 10.1016/j.autrev.2007.08.001, 17967728.
27. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993, 11:165-90. 10.1146/annurev.iy.11.040193.001121, 8386517.
28. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science 1992, 258:593-7. 10.1126/science.1411569, 1411569.
29. Zvonic S, Baugh JE, Arbour-Reily P, Mynatt RL, Stephens JM. Cross-talk among gp130 cytokines in adipocytes. J Biol Chem 2005, 280:33856-63. 10.1074/jbc.M508020200, 16096272.
30. Fairhurst AM, Wandstrat AE, Wakeland EK. Systemic lupus erythematosus: multiple immunological phenotypes in a complex genetic disease. Adv Immunol 2006, 92:1-69. full_text, 17145301.
31. Davidson A, Aranow C. Lupus nephritis: lessons from murine models. Nat Rev Rheumatol 2010, 6:13-20. 10.1038/nrrheum.2009.240, 19949431.
32. Dubois EL, Horowitz RE, Demopoulos HB, Teplitz R. NZB/NZW mice as a model of systemic lupus erythematosus. Jama 1966, 195:285-9. 10.1001/jama.195.4.285, 4159181.
33. MAM Philip CL. Animal Models for SLE. Current Protocols in Immunology 2002, 15:15.20.1-15.20.22. Hoboken, NJ: John Wiley & Sons, Inc.
34. Campbell IK, Bendele A, Smith DA, Hamilton JA. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis 1997, 56:364-8. 10.1136/ard.56.6.364, 1752394, 9227165.
35. Alexopoulou L, Pasparakis M, Kollias G. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 1997, 27:2588-92. 10.1002/eji.1830271018, 9368614.
36. Shiao RT, Miglietta L, Khera SY, Wolfson A, Freter CE. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. Leuk Lymphoma 1995, 17:485-94. 10.3109/10428199509056862, 7549842.
37. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54. 10.1038/nm976, 14702634.
38. H Y, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009, 9:798-809. 10.1038/nrc2734, 19851315.
39. Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S. PPAR Regulation of Inflammatory Signaling in CNS Diseases. PPAR Res 2008, 2008:658520. 2490815, 18670616.
40. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, Levy DE. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-6. 10.1126/science.1171721, 2840701, 19556508.
41. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem 2008, 15:834-43. 10.2174/092986708783955464, 18473793.
42. Kikkawa E, Yamashita M, Kimura M, Omori M, Sugaya K, Shimizu C, Katsumoto T, Ikekita M, Taniguchi M, Nakayama T. T(h)1/T(h)2 cell differentiation of developing CD4 single-positive thymocytes. Int Immunol 2002, 14:943-51. 10.1093/intimm/dxf057, 12147631.
43. Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, Kung AL, Cereb N, Yao TP, Yang SY, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science 2001, 292:1907-10. 10.1126/science.1059835, 11397944.
44. Shi M, Lin TH, Appell KC, Berg LJ. Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 2008, 28:763-73. 10.1016/j.immuni.2008.04.016, 2587400, 18549798.
45. Antonelli A, Bianchi M, Crinelli R, Gentilini L, Magnani M. Modulation of ICAM-1 expression in ECV304 cells by macrophage-released cytokines. Blood Cells Mol Dis 2001, 27:978-91. 10.1006/bcmd.2001.0470, 11831864.
46. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004, 50:3408-17. 10.1002/art.20583, 15529366.
47. Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, Lee JL, Ahn JS, Moon JH, Shin HJ, et al. Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. Clin Lymphoma Myeloma Leuk 2010, 10:62-7. 10.3816/CLML.2010.n.007, 20223731.
48. Spies CM, Bijlsma JW, Burmester GR, Buttgereit F. Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol 2010, 10:302-7. 10.1016/j.coph.2010.02.001, 20202903.